In terms of HER2 status, both non-screeners and those who are unaware were less likely to be diagnosed with HER2-negative cancers (non-screeners ORHER2-negative vs HER2-positive (reference): 0.80 [0.67–0.96], p = 0.016; unaware ORHER2-negative vs HER2-positive (reference): 0.72 [0.53–0.97], p = 0.028). This evidence concerns the gene ERBB2 and cancer.